Skip to Content

Rilonacept Pregnancy and Breastfeeding Warnings

Rilonacept is also known as: Arcalyst

Medically reviewed by Last updated on Nov 5, 2020.

Rilonacept Pregnancy Warnings

Animal studies have revealed evidence of an increase in the number of stillbirths, an increased incidence of lumbar ribs, and one case of multiple fusion and absence of the ribs and thoracic vertebral bodies and arches. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is not recommended.

US FDA pregnancy category: C

-Based on animal studies, this drug can cause fetal harm.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

See references

Rilonacept Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

-The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.

References for breastfeeding information

  1. "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.